Hagens berman, national trial attorneys, encourages y-mabs therapeutics (ymab) investors with significant losses to contact the firm's attorneys, securities fraud class action pending

San francisco, california--(newsfile corp. - january 23, 2023) - hagens berman urges y-mabs therapeutics, inc. (nasdaq: ymab) investors who suffered significant losses to submit your losses now.class period: oct. 6, 2020 - oct. 28, 2022lead plaintiff deadline: mar. 20, 2023visit: www.hbsslaw.com/investor-fraud/ymabcontact an attorney now: ymab@hbsslaw.com844-916-0895y-mabs therapeutics, inc. (nasdaq: ymab) securities fraud class action: the litigation focuses on y-mabs' past assurances that its biologics license application ("bla") f
YMAB Ratings Summary
YMAB Quant Ranking